BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37963297)

  • 21. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
    Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
    Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.
    Sharma A; Kirkpatrick G; Chen V; Skolnik K; Hollander Z; Wilcox P; Quon BS
    PLoS One; 2017; 12(2):e0171229. PubMed ID: 28178305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
    Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ
    J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
    West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
    Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
    Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
    [No Abstract]   [Full Text] [Related]  

  • 28. Respiratory viruses: What is their role in acute exacerbations in children with cystic fibrosis?
    Hizal M; Yalcin E; Alp A; Ozden M; Karakaya J; Eryilmaz Polat S; Tugcu G; Dogru D; Ozcelik U; Kiper N
    Pediatr Pulmonol; 2020 Jul; 55(7):1646-1652. PubMed ID: 32227679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Clinical Association between
    O'Dea AL; Feng R; Glaser LJ; Kubrak C; Rubenstein RC; Dorgan DJ; Hadjiliadis D; Kawut SM; Hong G
    Ann Am Thorac Soc; 2023 Jul; 20(7):984-992. PubMed ID: 36800434
    [No Abstract]   [Full Text] [Related]  

  • 30. BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis.
    Schultz A; McLeod C; Berry S; Marsh J; McKenzie A; Messer M; Wood J; Saville B; Jaffe A; Ranganathan S; Stick S; Wark P; Webb S; Snelling T
    Trials; 2023 Mar; 24(1):211. PubMed ID: 36949472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of the weather on pulmonary exacerbations and viral infections among adults with cystic fibrosis.
    Flight WG; Bright-Thomas RJ; Sarran C; Mutton KJ; Morris J; Webb AK; Jones AM
    Int J Biometeorol; 2014 Nov; 58(9):1845-51. PubMed ID: 24452385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
    Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
    Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
    Lee TW; Southern KW; Perry LA; Penny-Dimri JC; Aslam AA
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005599. PubMed ID: 27314455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.
    Sanders DB; Khan U; Heltshe SL; Skalland M; West NE; VanDevanter DR; Goss CH; Flume PA;
    J Cyst Fibros; 2022 Jul; 21(4):574-580. PubMed ID: 34857494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
    Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
    J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.
    Wolter DJ; Onchiri FM; Emerson J; Precit MR; Lee M; McNamara S; Nay L; Blackledge M; Uluer A; Orenstein DM; Mann M; Hoover W; Gibson RL; Burns JL; Hoffman LR;
    Lancet Respir Med; 2019 Dec; 7(12):1027-1038. PubMed ID: 31727592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.
    Nash EF; Choyce J; Carrolan V; Justice E; Shaw KL; Sitch A; Mistry H; Whitehouse JL
    Ther Adv Respir Dis; 2022; 16():17534666211070133. PubMed ID: 35274585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
    Flume PA; Wainwright CE; Elizabeth Tullis D; Rodriguez S; Niknian M; Higgins M; Davies JC; Wagener JS
    J Cyst Fibros; 2018 Jan; 17(1):83-88. PubMed ID: 28651844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
    J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.